NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (iBio or the Company), a biotechnology innovator and biologics contract manufacturing organization, today announced that it has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. (Planet) for the development of Planets COVID-19 therapeutic candidate, ACE2-Fc.

ACE2-Fc is a recombinant protein comprised of human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment (Fc). As an immunoadhesin, ACE2-Fc targets the coronavirus virions directly by using the ACE2 extracellular domain as a decoy to bind the spike protein and block infection of healthy cells, while the fused Fc domain prolongs the life of the protein in circulation. The design is expected to bring the benefit of a traditional neutralizing antibody while prospectively limiting the potential for viral escape given that ACE2 is also the target receptor for coronavirus for cell entry. Planets in vitro studies demonstrated that its ACE2-Fc blocks SARS-CoV-2 virus from infecting Vero E6 cells.

Under the terms of the agreement, iBio obtained an exclusive license to Planets ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.

We see tremendous opportunity in our partnership with Planet to develop this novel immunoadhesin molecule as a potential COVID-19 disease treatment, said Tom Isett, Chairman & CEO of iBio. We believe the molecule may be effective against SARS-CoV-2 infection, and that it has the potential to be rapidly re-designed in the FastPharming System to address mutations in the current virus, if any, as well as future coronaviral diseases.

Elliot Fineman, Planets President and CEO, commented, iBio is an ideal partner for Planet, offering experience in manufacturing plant-based biopharmaceuticals and rapid scale-up capabilities. We are eager to support iBio in the pre-clinical development of ACE2-Fc.

About Planet Biotechnology Inc.

Scientists at Planet Biotechnology identify and develop promising antibodies and receptor/ligand-Fc fusion proteins for the treatment and prevention of disease. Planets anti-infective programs focus on tick-borne diseases, coronaviruses, and multi-drug resistant pathogens. The Company uses a plant-based expression system to rapidly produce its antibody and receptor/ligand-Fc products.

About iBios COVID-19 Programs

On March 11, 2020, the Company filed four provisional patent applications with the U.S. Patent and Trademark Office in support of its COVID-19 vaccine platforms. The Company subsequently announced its virus-like particle (VLP) program (IBIO-200) and LicKM-Subunit vaccine program (IBIO-201) on March 18, and June 3, 2020, respectively, and pre-clinical studies were subsequently initiated. On August 27, 2020, the Company secured exclusive worldwide rights to an ACE2-Fc antibody therapeutic from Planet Biotechnology, Inc. If any of the COVID-19 biopharmaceutical development program(s) move into clinical trials, iBio has the capability to manufacture product candidates at clinical and commercial scales in its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBios FastPharming Facility was part of the Blue Angel initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Companys subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBios FastGlycaneering Development Service includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, as well as vaccines and therapeutics for COVID-19 disease. For more information, visit http://www.ibioinc.com.

FORWARD-LOOKING STATEMENTSCertain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the development of the novel immunoadhesin molecule as a potential COVID-19 disease treatment, the design bringing the benefits of a traditional neutralizing antibody while prospectively limiting the potential for viral escape given that ACE2 is also the target receptor for coronavirus for cell entry, the molecule being effective against SARS-CoV-2 infection, and that it has the potential to be rapidly re-designed in the FastPharming System to address mutations in the current virus, if any, as well as future coronaviral diseases. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the partnership with Planet being successful, the ability to develop the novel immunoadhesin molecule as a potential COVID-19 disease treatment and mutations in the current virus, the Companys ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Companys Annual Report on Form 10-K for the year ended June 30, 2019 and the Companys subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contacts:

Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580 skilmer@ibioinc.com

Original post:
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic - GlobeNewswire

Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations

Tel Aviv, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that the leadership will be presenting at the Cell & Gene Meeting on the Mesa, which is being held from October 12th 16th. In addition to providing an overview of the Company, the management team will provide a progress update on the clinical and development programs and an overview of the Companys business strategy. Management will be virtually meeting cell and gene therapy companies to support collaborations.

This is one of the most prestigious meetings for our industry, and despite it being virtual this year due to the COVID-19 pandemic, it will not dampen our enthusiasm commented Dr. Yarkoni. We have successfully adjusted our operations, and we continue to make significant progress with our Israel and U.S.-based clinical trials. We are also taking meaningful steps to accelerate nearer-term revenue opportunities as we are collaborating with several partners that are looking to leverage our technology platform to help improve their products, especially in high-growth areas such as CAR T, NK (natural killers) and MSCs. We are looking forward to sharing the progress we have made and also look forward to meeting with current and potential partners developing cell and gene therapies.

To schedule a meeting with the Companys Chief Executive Officer, Dr. Shai Yarkoni or Chief Operating Officer, Amos Ofer, please request a meeting through the meeting portal and/or contact the Company direct at shai@cellect.co or amoso@cellect.co. The presentation will be available on the Companys website prior to the commencement of the meeting. The Cell & Gene Meeting on the Mesa is the sectors foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the functional selection of cells that aims to improve the robustness, safety and efficacy of a variety of cell and gene therapies. The Companys technology can be used by researchers, clinical community and pharma companies in a wide variety of applications including next generation Car T, NK, MSC and gene therapies.

The Company is also developing its own product that is an improved BMT which is in a current clinical trial for cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Companys expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should, could, might, seek, target, will, project, forecast, continue or anticipate or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellects expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Companys history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Companys ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Companys ability to obtain regulatory approvals; the Companys ability to obtain favorable pre-clinical and clinical trial results; the Companys technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Companys clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Companys ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Companys industry; unforeseen scientific difficulties may develop with the Companys technology; the Companys ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Companys ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in Cellect Biotechnology Ltd.s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SECs website, http://www.sec.gov, and in the Companys periodic filings with the SEC.

ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444

Or

EVC Group LLCMichael Polyviou(732) 933-2754mpolyviou@evcgroup.com

Read the rest here:
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa - GlobeNewswire

Debut Bio

SAN DIEGO (PRWEB) September 15, 2020

Debut Biotechnology, a UC-Irvine spinout advancing scalable cell-free biomanufacturing, today announced that it has been awarded $1M from the Air Force Research Labs Biotechnology Grand Challenge. Debut Bio is the inaugural recipient of the award, which honors the companys proposal on biosynthesis of monomers for aerospace applications.

In the proposal, Debut Bio details its ability to leverage the companys scalable biomanufacturing platform for bio- and metal-free synthesis of polymer precursors relevant for the aerospace industry. Debut Bios platform will provide AFRL with the ability to effectively and efficiently biomanufacture specialty ingredients needed for aerospace applications. In doing so, Debut Bio expects to reduce aerospace material costs and improve vehicle maintenance processes by extending service lifetimes.

The Air Force Research Lab has a well-documented history in discovering and leveraging breakthrough technologies. By offering a cell-free, continuous biomanufacturing process, we are excited to continue that legacy of innovation through our work with them, said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Cell-free biomanufacturing enables the quality manufacturing of high-value molecules at a price point that scales far beyond what is possible today. In bringing this approach to the AFRL, we hope to usher in a new era of biomanufacturing for high-value molecules that is scalable, economically viable, and results in solutions that are efficient and effective.

Debut Bio has applied its technology to the pharmaceutical and specialty ingredient industries, allowing customers to manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high-value specialty chemicals.

The Debut Biotechnology proposal provides a path to a scalable, bio- and metal free synthesis of key aerospace polymer precursors, explained Dr. Davide Simone, AFRLs technology advisor for biosynthesis of monomers for aerospace thermosets and senior research chemist. Expected benefits for the Air Force include a significant savings in composite aerospace structural material costs and the elimination of oxidation promoting metal catalysts from structural components, extending service lifetimes.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional materials manufacturing and avoids the use of environmentally harmful chemical synthesis. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing or extraction of ingredients from plants and other sources.

In Debut Bios system, materials are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based fermentation systems. The platform technology operates under a continuous manufacturing regime, allowing Debut Bio to scale beyond the capabilities of other manufacturing processes currently on the market, which are constrained by the precipitation of enzymes, the need for multiple large reactors, and the specific requirements of enzymes. By leveraging continuous manufacturing, Debut Bio is able to drive down the cost of cell-free manufacturing to provide scale, consistency, novelty, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio serves organizations across the defense and specialty ingredient industries, with commitments from several large scale manufacturers to integrate its platform into their existing pipelines.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Weiss, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Continued here:
Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications - PR Web

The Australian government needs to develop a bold vision and strategic plan to create the data-driven healthcare system and bioeconomy of the future.

In my new report for ASPI, Biodata and biotechnology: Opportunity and challenges for Australia, I explain how the extraordinary developments in genome sequencing and genetic engineering will transform all biological enterprises, especially healthcare, and create new ones, like the electronic revolution. I explain why Australia should harness and capitalise on our high-quality biomedical science, agricultural research and development, and healthcare systems to realise a once-in-a-generation opportunity to play a leading role in a major economic revolution.

Biotechnology dates back over 6,000years to the domestication of wheat and the use of yeast for fermentation, but has entered the province of human design and invention as a consequence of the gene-cloning, gene-manipulation and genome-sequencing revolutions of the past 50years.

While often thought of in terms of drug development and genetic engineering, biotechnology is fundamentally becoming an information industry with a universe of applications.

Humans have acquired the ability to read the genetic programming and analyse the structure of the molecules of lifehow cells work, how were different from each other, and what makes a lime different from a lemon. Life has evolved the most exquisite nanomachinesprotein machines that can bind oxygen and almost any other type of molecule; trap photons to turn carbon dioxide and water into carbohydrates; detect electric fields or sound waves and turn them into visual images; pump ions; facilitate the entry of viruses, bacteria and parasites into cells; and make molecular motors that spin or contract to trap prey, exert force and move.

The extraordinary advances in DNA sequencing are leading to an avalanche of genomic information. Genetic engineering can now be done with high speed and precision. The pace of change is accelerating, and biological technologies are intersecting with optical technologies, nanotechnologies, advanced computing and artificial intelligence to create possibilities that were, if not beyond imagination, well beyond feasibility just a few years ago.

The advent of population-scale genomic and smart sensor data will transform health care, health economics, medical research and drug development. It will also transform the national economy and create digital products that can be exported to the world. To achieve this, the Australian government needs a strategic plan for acquiring genomic, clinical, pharmaceutical, sensor and patient self-reporting data and for providing trusted online evidence-based analysis of that information and advice to healthcare practitioners and citizens.

Governments also need to convince citizens of the personal and national value of big data in health care, and the privacy and security of that data, using a model that combines political leadership with subject-matter expertise.

The Australian government should establish a secure national repository for genomic and phenotypic data for research and healthcare use. This de-identified data should be made available to Australian researchers and health system managers. It could be provided to external parties, such as pharmaceutical companies, under appropriate conditions in exchange for early access to expensive treatments or shared benefits.

The Australian government should establish a central unit to assemble and supply evidence-based, well-curated and continuously updated genomic analysis, integrated with clinical and other data, and linked to national treatment guidelines, for decision support at the point of care.

The cost of doing this will be trivial compared with other costs in the healthcare system, and trivial in relation to the cost reductions and healthcare improvements that it will enable. This work could be funded from the Medical Research Future Fund and publicprivate partnerships.

Smart sensors should be made available through Medicare and routinely installed in hospitals, clinics and other healthcare settings, such as aged-care homes.

Conversion to electronic health records should be mandatory for all healthcare providers receiving government support or reimbursement in Australia, as recommended by the Australian Academy of Technology and Engineering.

Genetic tests should be progressively upgraded to whole-genome sequencing to build the national genomic estate. That would convert diagnostic expenses into an enduring strategic asset.

All suitably accredited health professionals, including general practitioners, should be able to obtain a genomic report, pharmacogenomic advice, early warning of an incipient disease, or any combination of that information, about a patient (with patient approval) upon request, and bulletins issued where relevant. Citizens should also be entitled to access such information in the interests of caring for their own health, provided it is conservative and actionable.

Security and police agencies should establish internal expertise in biotechnology and biodata analysis. They should have access to national genomic information under defined circumstances and subject to judicial approval and oversight.

Major investment funds and relevant government departments should consider establishing bio-intelligence units to keep abreast of opportunities and incorporate those opportunities into their strategic planning. Australian research funding agencies and the CSIRO should continue to invest in advanced genetic engineering and vaccine and drug development. Superannuation funds should be encouraged to invest at least 1% of their resources into domestic start-up and early-phase high-tech and digital enterprises, especially in health and biotechnologies.

Universities should provide training in computer programming and big-data analysis as a core component of all science and engineering degrees.

Originally posted here:
Australia can take the lead in biotechnology revolution | The Strategist - The Strategist

BEDFORD, N.H., Aug. 27, 2020 /PRNewswire/ --LSNE Contract Manufacturing, a leading contract development and manufacturing organization, is pleased to announce that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical stage biotechnology based therapeutic products at its aseptic fill finish facility in Len, Spain. This important approval builds upon LSNE's well-established capabilities in providing aseptic fill finish of biologic products for clients at its US facilities. These products include monoclonal antibodies, fusion proteins, replacement enzymes, plasmids, capsids, and oligonucleotides.

"The authorization of biologic manufacturing for clinical drug product in both vial and pre-filled syringe (PFS) presentations is a vital step to our maturation of drug product manufacturing at our facility in Spain. This will provide the global market with more access to LSNE facilities for the manufacture of these high-value biologics, including monoclonal antibodies and other recombinant proteins," said Shawn Cain, LSNE's Chief Operating Officer.

Jaime Del Campo, Site Head at LSNE-Len said, "We are thrilled with this most recent milestone and our ongoing partnership with AEMPS. This is another big step forward supported by our industry leading quality and operations teams. We anticipate this authorization will have an immediate impact in our ability to support our client's varied clinical programs and ensures long-term benefits to their future commercial supply."

About LSNE

LSNE is a privately held company with six GMP facilities four located in New Hampshire, one in Wisconsin and one located in Len, Spain. LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology, and medical device industries since 1997, specializing in a wide range of services including process cycle development, fill-finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), and analytical testing. Through the thoughtful integration of six processing facilities, qualified staffing, and extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a global market.

Media Contact

Jeff ClementVice President of Business Development(603) 668-5763[emailprotected]www.lyophilization.com

SOURCE LSNE Contract Manufacturing

http://www.lyophilization.com

More here:
LSNE-Len Receives Approval From AEMPS To Manufacture Biotechnology Based Therapeutic Products - PRNewswire

A rating of 83 puts Adaptimmune Therapeutics PLC - ADR (ADAP) near the top of the Biotechnology industry according to InvestorsObserver. Adaptimmune Therapeutics PLC - ADR's score of 83 means it scores higher than 83% of stocks in the industry. Adaptimmune Therapeutics PLC - ADR also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is down -5.53% while the S&P 500 is up 0.31% as of 1:26 PM on Friday, Aug 28. ADAP is lower by -$0.45 from the previous closing price of $8.14 on volume of 849,165 shares. Over the past year the S&P 500 is higher by 19.52% while ADAP is up 380.63%. ADAP lost -$1.10 per share the over the last 12 months.

To screen for more stocks like ADAP click here.

Original post:
Should You Buy Adaptimmune Therapeutics PLC - ADR (ADAP) in Biotechnology Industry? - InvestorsObserver

A rating of 95 puts Cytokinetics, Inc. (CYTK) near the top of the Biotechnology industry according to InvestorsObserver. Cytokinetics, Inc.'s score of 95 means it scores higher than 95% of stocks in the industry. Cytokinetics, Inc. also received an overall rating of 77, putting it above 77% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 77 means the stock is more attractive than 77 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cytokinetics, Inc. (CYTK) stock is trading at $24.50 as of 2:24 PM on Friday, Aug 28, a gain of $0.86, or 3.64% from the previous closing price of $23.64. The stock has traded between $23.65 and $24.95 so far today. Volume today is 824,667 compared to average volume of 1,027,773.

To see the top 5 stocks in Biotechnology click here.

Link:
Is Cytokinetics, Inc. (CYTK) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Food Biotechnology market.

Trusted Business Insights presents an updated and Latest Study on Food Biotechnology Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Food Biotechnology market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Food Biotechnology MarketIndustry / Sector Trends

Global Food Biotechnology Market size was valued at over USD 23 billion in 2018 and is anticipated to witness over 10% CAGR up to 2025.

Increasing penetration of advanced technologies to develop new products by modifying plants, animals, and microorganisms genes to provide innovative solutions is driving the market growth. Shifting trends towards healthy lifestyles accompanied by a rise in processed food demand has urged the F&B manufacturers to improve the nutritional content in their products, thereby generating new growth opportunities for the biotech-based industry players. Further, there is a requirement to enhance the shelf life and taste of food by the use of encapsulation techniques and other ingredients.

Strong growth in functional food & beverages and dietary supplements industry is resulting in increased competitiveness, thus propelling the food biotechnology market revenue. As per CCI, the global nutraceutical market including functional F&B and dietary supplements is projected to reach USD 241 billion in 2019, observing around 7% CAGR from 2014 to 2019. Factors such as robust expansion of food industry and low-cost biotech services particular in developing countries has escalated the adoption of services.

Stringent government regulations to enhance product quality and transparency are among the foremost aspects attributing to food biotech solutions. Also, modifications in labeling regulations asking for a declaration of GMOs, allergens, and nutritional content is surging the industry share. Further, consumer-driven movements such as clean label has urged food manufacturers to improve the quality by using natural ingredients instead of artificial constituents.

Changes in climatic conditions over the years has resulted in increased production of genetically modified (GM) crops or ingredients through the use of biotech services. This provides plants with improved resistance to diseases, insecticides, and herbicides, as well as extending the shelf life of the produce. However, growth in the organic food industry can hamper the demand for GM crops, thus affecting the food biotechnology industry share.

Market Segmentation, Outlook & Regional Insights: Food Biotechnology Market

Food Biotechnology Market, By Type

Transgenic segment dominates the global market accounting for over 75% share in 2018. Increasing demand for genetically modified crops to enhance productivity in low producing or harsh climatic conditions will drive segment growth. According to ISAAA, the global utilized area for biotech crops increased from 148 million hectares in 2010 to 190 million hectares in 2017. Countries including the U.S., Brazil, Argentina, Canada, and India holds over 90% of the total area under GM crop cultivation. Farmers shifting from conventional seeds to bio-seeds to improve their profit margins will escalate the market growth.

Germany Food Biotechnology Market Size, By Type, 2018 (USD Million)

Food Biotechnology Market, By Application

Global food biotechnology market through animal segment holds over 34% share in 2018. Increasing necessity to enhance milk production in dairy cattle with growing demand will propel industry expansion. Robust growth in meat consumption such as processed meat accompanied by increasing consumer awareness on nutritional benefits will drive the biotech applications. As per FAO, global meat production is projected to increase, reach around 48MT by 2025. Further, testing services for developing products to suit the human dietary requirements will drive market development.

Global food biotechnology market through plants is projected to account for over USD 22 billion in 2025. The key growth factors include an increase in the development of GM crops with pesticide resistance and abiotic stress tolerance to increase the yield. Reduction in the arable land area will further shift the preference towards biotechnological products. Enhanced focus on innovation of new food ingredients will surge the business revenues. Strong application outlook of biotech solutions to produce high-quality crops and reduce the health risk will augment business expansion.

Food Biotechnology Market, By Region

North America market is anticipated to cross USD 12 billion by 2025. High investments on technological advancements coupled with high consumer spending on nutritious products will augment the industry share. The U.S. is the largest producer of genetically modified crops with 75 million hectares area for biotech crops. Further, the presence of large multinational corporations, increasing private and government R&D investments, supported by favourable government policies will fuel the market growth. Further, positive application outlook of genetically modified yeast in developing new alcoholic beverages will support regional growth.

Asia Pacific Food Biotechnology Market, By Country, 2018 & 2025, (USD Million)

Asia Pacific food biotechnology market is projected to witness over 11% CAGR from 2019 to 2025. Countries including China, India, and Japan together dominate the regional market share. The demand for dietary supplements is increasing due to a shifting trend towards healthy lifestyles, thus increasing the demand for nutritional ingredients. Also, product innovations supported by the rise in per capita income will drive the biotech solutions on health foods. Further, the necessity to augment the agricultural output owing to the rise in population, along with severe climatic variations will drive the biotechnology industry share.

Key Players, Recent Developments & Sector Viewpoints: Food Biotechnology Market

Global market is competitive due to the presence of large multinationals and regional players. Key industry participants in market include BASF SE, Bayer CropScience AG, AquaBounty Technologies, ABS Global, Dow AgroSciences LLC, Arcadia Biosciences, Camson Bio Technologies Ltd, BDF Ingredients Zuchem, and Monsanto. Product development, geographic expansion, mergers, acquisitions, and collaborations are among the key strategies observed in the industry. For instance, in 2017, Bayer and Ginkgo Bioworks announced to launch a company to developing new technologies for engineering the plant microbiome.

Industry Viewpoint

Food biotechnology market is driven by the requirement for improving the productivity and quality of the edible items by altering genes. Growth in the food & beverages industry, increasing population, rising disposable incomes, and health awareness are among the major factors creating a long-term positive impact. Biotechnological product innovations among food manufacturers will provide lucrative opportunities for business growth. North America and Europe are among the early adopters of biotech services, however developing regions are also expected to implement advanced solutions in food industry. The penetration rate is high in Asia Pacific owing to strong R&D investments and the necessity for increasing the food productivity and animal milk output

Key Insights Covered: Exhaustive Food Biotechnology Market1. Market size (sales, revenue and growth rate) of Food Biotechnology industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Food Biotechnology industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Food Biotechnology industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Food Biotechnology industry.

Research Methodology: Food Biotechnology Market

Looking for more? Check out our repository for all available reports on Food Biotechnology in related sectors.

Quick Read Table of Contents of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See original here:
Food Biotechnology Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The Scarlet

The 62 rating InvestorsObserver gives to Trevena Inc (TRVN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, TRVNs 62 overall rating means the stock scores better than 62 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trevena Inc (TRVN) stock is trading at $1.68 as of 9:51 AM on Friday, Aug 28, a rise of $0.11, or 7.01% from the previous closing price of $1.57. The stock has traded between $1.68 and $1.89 so far today. Volume today is low. So far 3,619,286 shares have traded compared to average volume of 15,506,572 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original post:
Is Trevena Inc (TRVN) The Right Choice in Biotechnology? - InvestorsObserver

The 41 rating InvestorsObserver gives to Tyme Technologies Inc (TYME) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 33 percent of stocks in the Biotechnology industry, TYMEs 41 overall rating means the stock scores better than 41 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 41 would rank higher than 41 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Tyme Technologies Inc (TYME) stock has fallen -5.26% while the S&P 500 has gained 0.33% as of 2:25 PM on Friday, Aug 28. TYME is down -$0.06 from the previous closing price of $1.14 on volume of 1,253,542 shares. Over the past year the S&P 500 is up 19.54% while TYME is down -6.90%. TYME lost -$0.23 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Go here to see the original:
Is Tyme Technologies Inc (TYME) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Syros Pharmaceuticals Inc (SYRS) is near the middle in its industry group according to InvestorsObserver. SYRS gets an overall rating of 57. That means it scores higher than 57 percent of stocks. Syros Pharmaceuticals Inc gets a 65 rank in the Biotechnology industry. Biotechnology is number 26 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 57 means the stock is more attractive than 57 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is down -2.84% while the S&P 500 is higher by 0.33% as of 2:23 PM on Friday, Aug 28. SYRS has fallen -$0.38 from the previous closing price of $13.39 on volume of 312,289 shares. Over the past year the S&P 500 is up 19.54% while SYRS is higher by 18.60%. SYRS lost -$1.69 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Syros Pharmaceuticals Inc click here.

More:
Is Syros Pharmaceuticals Inc (SYRS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Global Pharmaceuticals and Biotechnology R&D Market: Trends Estimates High Demand by 2027

The Pharmaceuticals and Biotechnology R&D Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Pharmaceuticals and Biotechnology R&D Industry Report is an in-depth study analyzing the current state of the Pharmaceuticals and Biotechnology R&D Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Pharmaceuticals and Biotechnology R&D Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Pharmaceuticals and Biotechnology R&D market. All findings and data on the global Pharmaceuticals and Biotechnology R&D market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Pharmaceuticals and Biotechnology R&D market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Pharmaceuticals and Biotechnology R&D industry.

Some of The Companies Competing in The Pharmaceuticals and Biotechnology R&D Market are: ROCHE, JOHNSON & JOHNSON, MERCK, NOVARTIS, PFIZER, SANOFI, BAYER, BRISTOL-MYERS SQUIBB, ASTRAZENECA, GLAXOSMITHKLINE, ABBVIE, ELI LILLY, BOEHRINGER SOHN, AMGEN, GILEAD SCIENCES, TAKEDA PHARMACEUTICAL, NOVO NORDISK, BIOGEN, ABBOTT, ASTELLAS PHARMA, and TEVA PHARMACEUTICAL INDUSTRIES

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/global-pharmaceuticals-and-biotechnology-r-d-market-size-status-and-forecast-2020-2026?utm_source=newsdistinct&utm_medium=24

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Pharmaceuticals and Biotechnology R&D Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Pharmaceuticals and Biotechnology R&D Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Pharmaceuticals and Biotechnology R&D market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Pharmaceuticals and Biotechnology R&D market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Pharmaceuticals and Biotechnology R&D market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Pharmaceuticals and Biotechnology R&D market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Pharmaceuticals and Biotechnology R&D Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Pharmaceuticals and Biotechnology R&D Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Pharmaceuticals and Biotechnology R&D Market Effect Factors Analysis

Chapter 12: GlobalPharmaceuticals and Biotechnology R&D Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/global-pharmaceuticals-and-biotechnology-r-d-market-size-status-and-forecast-2020-2026?utm_source=newsdistinct&utm_medium=24

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more:
Research on Pharmaceuticals and Biotechnology R&D Market (impact of COVID-19) with Top Players: ROCHE, JOHNSON & JOHNSON, MERCK, NOVARTIS, PFIZER,...

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Biotechnology market demand is anticipated to flourish during the forecast period 2018-2026. The report offers information related to import and export, along with the current business chain in the market at the global level. This report provides an in-depth overview of the Biotechnology market. This includes market characteristics, consisting of segmentation, market share, trends and strategies for this market. The Market Size section provides historical forecasts of market growth and future. An in-depth analysis of the major companies operating in the market is also mentioned in this research report.

Get FREE PDF Brochure Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/4025

The global Biotechnology market is segmented on the basis of type and application.

It also provides market size and forecast estimates from the year 2018 to 2026 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and South America (SAM). The Biotechnology market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of top countries globally along with the current trend and opportunities prevailing in the region.

A thorough examination of the Biotechnology market includes each and every aspect, which begins with knowing the market, speaking with clients, and evaluating the complete data of the global market. For more clarification, the global market is segmented on the basis of the manufacture of the kind of products, and their applications. The report also delivers information as per the regions based on the geographical classification of the global Biotechnology market. The dynamic foundation of the global market is based on the calculation of product supply in different markets, their revenues, capability, and a chain of production.

Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information.

Competitive Section

Key players operating the Biotechnology market are Abbott Laboratories, Amgen Inc., GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Inc., Roche, and Sanofi Aventis.

Furthermore, this study will help our clients solve the following issues:

Market dynamics- The study foresees dynamics of industries by using core analytical and unconventional market research approaches. This will help clients to use this insight provided to maneuver themselves through market uncertainties and disruptions

Identifying key cannibalizes Strong substitute for a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance

Spotting emerging trends-Our Ecosystem offering helps clients to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have early mover advantage

Interrelated opportunities- This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/4025

All in all, the Biotechnology market research study elucidates a detailed evaluation of this business and projects this industry to register a commendable growth rate in the forthcoming years. The Biotechnology market analysis report also delivers important insights with respect to aspects such as the volume of sales, valuation forecast, market size, and the market competition trends as well as the market concentration rate.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

View post:
Biotechnology Market Size Research, Business Opportunities, Top Manufacture, Industry Growth, Industry Share Report, Regional Analysis and Global...

iTeos Therapeutics Inc (ITOS) is around the top of the Biotechnology industry according to InvestorsObserver. ITOS received an overall rating of 51, which means that it scores higher than 51 percent of all stocks. iTeos Therapeutics Inc also achieved a score of 86 in the Biotechnology industry, putting it above 86 percent of Biotechnology stocks. Biotechnology is ranked 110 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

iTeos Therapeutics Inc (ITOS) stock has fallen -7.13% while the S&P 500 has gained 0.42% as of 2:44 PM on Tuesday, Jun 22. ITOS is lower by -$1.74 from the previous closing price of $24.48 on volume of 654,547 shares. Over the past year the S&P 500 has gained 31.93% while ITOS has gained 19.37%. ITOS lost -$1.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on iTeos Therapeutics Inc (ITOS) Stock.

View post:
Is iTeos Therapeutics Inc (ITOS) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

The latest market report published by Reports and Data, titled Global Industrial Biotechnology Market, presents an accurate analysis of the estimated market size, share, revenue, and sales & distribution networks of the global Industrial Biotechnology market over the forecast period. The report offers an exhaustive overview of the market, along with a precise summary of the markets leading regions. Our team of analysts has studied the existing competitive landscape of the market inside out, focusing on the leading companies and their business expansion strategies. The report ends with conclusive data offering useful insights into the market growth on both regional and global levels.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

BASF, Amyris, Borregaard, BioAmber, Codexis, Evolva, Fermentalg, Gevo, Global Bioenergies, Deinove, Metabolic Explorer, Novozymes, and Solazyme

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1338

The report draws the focus of the reader on the grave impact of the ongoing COVID-19 pandemic on the Industrial Biotechnology industry and its vital segments and sub-segments. It elaborates on the adverse effects of the pandemic on the global economic scenario, as well as this particular business sphere. The report takes into account the key influencing factors influencing market performance in the present COVID-19 times. The market has been substantially affected by the pandemic, and significant changes have been observed in the market dynamics and demand trends. The report examines the major financial difficulties brought about by the pandemic and offers a future COVID-19 impact assessment.

The market intelligence study takes the reader through the key parameters of the Industrial Biotechnology market, including the strengths and weaknesses of the leading players, using analytical tools like the SWOT analysis and Porters Five Forces analysis. The report includes broad market segmentation based on the different product types, a wide application spectrum, the key regions, and the existing competition among players.

Type Outlook (Revenue, USD Million; 2016-2026)BiofuelBiochemicalBiomaterialBioType

Raw Material Outlook (Revenue, USD Million; 2016-2026)Grains & Starch CropsAgricultural ResiduesFood WasteForestry MaterialAnimal By-TypeEnergy CropsUrban & Suburban Waste

Application Outlook (Revenue, USD Million; 2016-2026)Food & FeedPharmaceuticalsPulp & PaperTextileBio Energy

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1338

The investigative study further assesses the market on the basis of market reach and consumer base in the key geographical segments. Alongside reviewing the sales network, distribution channels, pricing analysis, profit margins, cost and demand volatility, import/export dynamics, gross revenue, and various other aspects of the market, the report studies several factors affecting market growth over the forecast period, such as drivers, restraints, limitations, growth prospects, and numerous macro- and micro-economic indicators.

Key Geographies Encompassed in the Report:

Key questions addressed in the report:

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/industrial-biotechnology-market

Thank you for reading our report. For further queries regarding the report, please get in touch with us. Our team will ensure your report is customized as per your requirements.

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

See the original post here:
Industrial Biotechnology Market 2019 By Business Opportunity, Innovations, Applications, Upcoming-Trends, Growth-Analysis, Demand-Insight,...

A rating of 80 puts Cellectar Biosciences Inc (CLRB) near the top of the Biotechnology industry according to InvestorsObserver. Cellectar Biosciences Inc's score of 80 means it scores higher than 80% of stocks in the industry. Cellectar Biosciences Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 35 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cellectar Biosciences Inc (CLRB) stock is trading at $2.29 as of 2:18 PM on Thursday, Dec 3, an increase of $0.34, or 17.18% from the previous closing price of $1.95. The stock has traded between $1.95 and $2.40 so far today. Volume today is high. So far 8,826,004 shares have traded compared to average volume of 928,593 shares.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Read this article:
Is Cellectar Biosciences Inc (CLRB) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 64 rating InvestorsObserver gives to Gamida Cell Ltd (GMDA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 79 percent of stocks in the Biotechnology industry, GMDAs 64 overall rating means the stock scores better than 64 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 64 would rank higher than 64 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Gamida Cell Ltd (GMDA) stock has risen 0.38% while the S&P 500 is lower by -1.01% as of 10:57 AM on Thursday, Oct 15. GMDA is up $0.02 from the previous closing price of $5.20 on volume of 112,860 shares. Over the past year the S&P 500 is up 15.51% while GMDA is up 7.63%. GMDA lost -$1.26 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Gamida Cell Ltd (GMDA) Stock.

Continue reading here:
Is Gamida Cell Ltd (GMDA) a Winner in the Biotechnology Industry? - InvestorsObserver

Virus Purification Kits Market: Introduction

Transparency Market Research has published a new report titled Virus Purification Kits Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20202030. According to the report, the global virus purification kits market was valued at US$ 1.1 Bn in 2019. It is expected to expand at a CAGR of ~11% during the forecast period from 2020 to 2030. Recombinant viral vectors are highly promising tools for both in vitro and in vivo gene transfer, and oncolytic virus show encouraging results for cancer & other related treatment.

Virus purification kits provide fast and simple procedures to concentrate and purify viral vectors from cell lysate and cell culture media. A large number of vaccines are produced from cell-culture derived virus particles. Downstream purification strategies can be expensive and account for 70% of the overall manufacturing costs, which has been fueling the demand for innovative technologies for virus purification in the last few years. North America dominated the global virus purification kits market, in terms of revenue, in 2019. It is expected to continue its market dominance by the end of 2030.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36002

Rise in Research Funding by Public and Private Players to Drive Market

R&D is a vital source of innovation, as it contributes to critical knowledge-based assets as well as strengthens absorptive capacities. Furthermore, an increase in competition in the market is prompting companies to focus on R&D by allocating more resources, both in the form of investments and trained workforce. For instance, Danaher Corporations investment in research & development increased from ~US$ 956 Mn in 2017 to US$ 1.1 Bn in 2019. The higher yield of virus particles received with the help of virus purification kits is also fuelling the global virus purification kits market.

Increase in support from governmental bodies for biotechnology and pharmaceutical industries and consistent expansion of biopharmaceutical & biotechnology industries are major factors driving the global virus purification kits market.

Chromatography to be Lucrative Technology

Based on technology, the global virus purification kits market has been divided into ultracentrifugation, chromatography, nanofiltration, and others. The ultracentrifugation segment dominated the global virus purification kits market due to cost-effective methods and the availability of a large number of products by major companies. Chromatography is likely to be a highly lucrative segment during the forecast period, owing to faster processing time, higher recovery rate of virus, simple methods, and highly purified virus offered by this technology.

Request for Analysis of COVID-19 Impact on Virus Purification Kits Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=36002

Adenovirus Dominated Global Market

In terms of virus type, the global virus purification kits market has been segmented into adenovirus, lentivirus, retrovirus, and others. The adenovirus segment accounted for a major share of the market in 2019. It is expected to dominate the global virus purification kits market by 2030. Higher yield of adenovirus particles by latest virus purification kits, major application in viral vector based drugs, and rising incidence of adenoviruses-associated respiratory diseases are key drivers of the segment.

Contract Research Organizations (CROs) to be Promising End User

Based on end user, the global virus purification kits market has been divided into academic & research institutes, biopharmaceutical & biotechnology companies, contract research organizations (CROs), and others. The biopharmaceutical & biotechnology companies segment dominated the global virus purification kits market in 2019 due to the rise in adoption of biotherapeutics across the globe and research activities for drug discovery. Contract research organizations (CROs) is a highly lucrative segment, which is expected to expand at a high CAGR during the forecast period, owing to investments in R&D and initiation of research projects across the globe.

North America to Lead Global Market

In terms of region, the global virus purification kits market has been divided into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global virus purification kits market in 2019, owing to favorable policies & regulatory scenario established by governments for biopharmaceutical industries in the region, highly developed healthcare sector, increase in preference for biopharmaceuticals over conventional counterparts, and continuous evolution of technology. A survey report conducted by Pharmaceutical Researchers and Manufacturers of America (PhRMA) indicated that the total pharmaceutical R&D expenditure in the U.S. was US$ 48.6 Bn in 2011, which increased to US$ 71.4 Bn in 2017. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period due to the expansion of the healthcare sector, growing clinical trials for new drug development, and low cost of products and labor in the region.

Buy Virus Purification Kits Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=36002&ltype=S

Competition Landscape

The global virus purification kits market is fragmented in terms of number of players with entry of several new players in recent years. Key players in the global market include Merck KGaA, Danaher Corporation, Thermo Fisher Scientific, Inc., Sartorius AG, Lonza Group Ltd., Asahi Kasei Corporation, BioVision Inc., PendoTECH, QIAGEN, and Takara Bio Inc. Mergers, acquisitions & strategic collaborations, and new product & technology launches in recent years have been major strategies adopted by major companies in the virus purification kits market.

More Trending Reports by Transparency Market Research

Erectile Dysfunction Treatment Devices Market: https://www.biospace.com/article/-erectile-dysfunction-treatment-devices-market-lessening-stigma-and-more-awareness-likely-to-drive-the-growth-tmr/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

The rest is here:
Virus Purification Kits Market: Consistent Expansion of Biopharmaceutical and Biotechnology Industries Boosts the Global Market - Eurowire

Home News NTI convenes global experts on need for government oversight of biotechnology research

Shutterstock

The Nuclear Threat Initiative (NTI) convened a meeting of more than 40 experts worldwide to address the need for better oversight of biotechnology research.

Biotechnology research is essential for reducing pandemic threats and supporting global health. However, scientific advances in the life sciences, such as DNA synthesis and gene editing, are outpacing the ability of governments to provide effective oversight. Further, there is no international entity to uphold and oversee biosecurity norms, reduce biotechnology-related risks, and strengthen best practices for life science research oversight.

Without this oversight, the field is vulnerable to deliberate or accidental misuse of biotechnology. The COVID-19 pandemic has underscored the magnitude of these risks.

The attendees at this BTI meeting came from the United Nations, the biotech industry, philanthropies, academia, and non-governmental organizations. Addresses were delivered by Izumi Nakamitsu, under secretary general and high representative for disarmament affairs at the United Nations Office of Disarmament Affairs, and Arnaud Bernaert, head of shaping the future of health and healthcare at the World Economic Forum.

These global leaders discussed plans to establish an international entity for overseeing global biosecurity norms and best practices. The entity would have a systemic impact on the global biotechnology sector, bridging the gap between governance approaches developed by industry, civil society, and governments. They also discussed recent progress to create an international common mechanism for DNA synthesis screening.

Here is the original post:
NTI convenes global experts on need for government oversight of biotechnology research - Homeland Preparedness News

Evogene Ltd (EVGN) is near the top in its industry group according to InvestorsObserver. EVGN gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Evogene Ltd gets a 82 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Evogene Ltd (EVGN) stock is trading at $4.30 as of 10:42 AM on Monday, Oct 5, a rise of $0.60, or 16.22% from the previous closing price of $3.70. The stock has traded between $3.81 and $4.38 so far today. Volume today is less active than usual. So far 543,565 shares have traded compared to average volume of 1,332,960 shares.

Click Here to get the full Stock Score Report on Evogene Ltd (EVGN) Stock.

Originally posted here:
Is Evogene Ltd (EVGN) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver